Gregory Glenn
Net worth: 90 595 $ as of 2024-02-28
Profile
Gregory M. Glenn founded Intercell USA, Inc. Dr. Glenn is President-Research & Development at Novavax, Inc. He previously occupied the position of Chief Scientific Officer for Intercell AG, Chief Scientific Officer & Senior Vice President at Intercell USA, Inc., Research Scientist at Walter Reed Army Institute of Research and Associate-International Health at Johns Hopkins Bloomberg School of Public Health. Dr. Glenn received an undergraduate degree from Whitman College and a doctorate from Oral Roberts University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NOVAVAX, INC.
0.02% | 2023-04-17 | 18,339 ( 0.02% ) | 90 595 $ | 2024-02-28 |
Former positions of Gregory Glenn
Companies | Position | End |
---|---|---|
NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 2023-03-30 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 2009-12-31 |
IOMAI CORPORATION | Founder | 2007-12-31 |
Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
Johns Hopkins Bloomberg School of Public Health | Corporate Officer/Principal | - |
Training of Gregory Glenn
Oral Roberts University | Doctorate Degree |
Whitman College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NOVAVAX, INC. | Health Technology |
Private companies | 3 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Walter Reed Army Institute of Research |